An international research team led by the Institute of Bioengineering and Nanotechnology (IBN) of the Agency for Science, Technology and Research (A*STAR) and IBM Research developed a synthetic molecule that can kill five deadly types of multidrug-resistant bacteria with limited, if any, side effects. Their new material could be developed into an antimicrobial drug to treat patients with antibioticresistant infections.
This finding was reported in the scientific journal Nature Communications.
Superbugs that are resistant to antibiotics are a serious health threat. According to the UK Review on Antimicrobial Resistance, superbugs kill around 700,000 people worldwide each year. By 2050, 10 million people could die each year if existing antibiotics continue to lose their effectiveness.
“There is an urgent global need for new antimicrobials that are effective against superbugs. The situation has become more acute because bacteria are starting to develop resistance to the last-line antibiotics, which are given only to patients infected with bacteria resistant to available antibiotics,” said Professor Jackie Y. Ying, Executive Director of IBN.
The research community is trying to develop alternatives to antibiotics using synthetic polymers. However, the antimicrobial polymers developed so far are either too toxic for clinical use, not biodegradable or can only target one type of bacteria.
To address this problem, Dr Yi Yan Yang from IBN brought together a multidisciplinary research team from the US, China and Singapore to develop a new class of antimicrobial polymers called guanidinium-functionalized polycarbonates with a unique killing mechanism that can target a broad range of multidrug-resistant bacteria. It is biodegradable and non-toxic to human cells.
The polymer kills bacteria in the following way. First, the polymer binds specifically to the bacterial cell. Then, the polymer is transported across the bacterial cell membrane into the cytoplasm, where it causes precipitation of the cell contents (proteins and genes), resulting in cell death.
The team tested the polymers on mice infected with five hard-to-treat multidrug-resistant bacteria: Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, methicillinresistant Staphylococcus aureu and Pseudomonas aeruginosa. These superbugs are commonly acquired by patients in the hospitals and can cause systemic infections that lead to septic shock and multiple organ failure. The results showed that the bacteria were effectively removed from the mice and no toxicity was observed.
The researchers then further tested the effectiveness of the polymers on mice with two types of systemic infections caused by superbugs: peritonitis (an infection of the stomach’s inner lining) and lung infections from Pseudomonas aeruginosa. The polymers eliminated the bacterial infections in both groups of mice with negligible toxicity.
Dr Yi Yan Yang, Group Leader at IBN said, “We have demonstrated the first example of a biodegradable synthetic macromolecule with broad-spectrum antimicrobial activity in mice, unique killing mechanism and no toxicity. Once the polymer finishes its job of killing the bacteria, it will be naturally degraded after three days and will not remain in the body. This antimicrobial agent shows great promise for the treatment and prevention of multidrug-resistant systemic infections.”
“This study illustrates the potential for this new research field we denote as ‘macromolecular therapeutics’ to create entirely new classes of treatments for multiple diseases,” said Dr James Hedrick, Distinguished Research Staff Member, IBM Research – Almaden, San Jose, California. “In 2016, we demonstrated the efficacy of synthetic polymers to combat deadly viral diseases. The current research for treating bacterial infections rounds out our ability to someday treat a spectrum of infectious diseases with a single, new type of mechanism without the onset of resistance.”
To determine whether the bacteria will develop any resistance to the polymer, the team collaborated with Dr Paola Florez de Sessions at A*STAR’s Genome Institute of Singapore and the Cell Engineering group of Dr Simone Bianco at IBM Research – Almaden to perform genomic analysis. They found that the bacteria did not show any resistance development even after multiple treatments with the polymer.
The Latest on: Antimicrobial drug
via Google News
The Latest on: Antimicrobial drug
- Big Pharma Has Failed: The Antibiotic Pipeline Needs to Be Taken Under Public Ownershipon November 30, 2019 at 9:56 am
Over the last 80 years, human antibiotic use has selected for microbial populations that are increasingly effective at resisting our drugs. The pipeline for new antibiotics has become drier ever since ...
- Do past medicines hold the answer to antibiotic resistance?on November 30, 2019 at 4:28 am
baumannii. Antimicrobial selenium is a recognized dietary antioxidant, and the Food and Drug Administration (FDA) recommend it for daily intake. Other researchers have also found it to be a promising ...
- CDC Warning: Antibiotic-Resistant Fungal Infections Are Still a Big Problemon November 30, 2019 at 1:03 am
The cause of death was sepsis due to his echinocandin-resistant Candida infection, which, at the time, was uncommon in the U.S. This tragic case demonstrated to me firsthand the devastating impact of ...
- Antimicrobial Peptides Market to Witness a Pronounce Growth During 2019-2029on November 28, 2019 at 11:14 pm
The application of antimicrobial peptides in ailment of Hepatitis C, pneumonia, bacterial infections, HIV AIDS and cancer is expected to surge the acceptance towards the therapies. The institutional ...
- Antibiotic drug target identified by Indian researcherson November 28, 2019 at 3:10 am
Indian researchers have identified a protein pathway in an antibiotic-resistant bacterial strain called Staphylococcus aureus (S. aureus) and also a new molecule that can target this pathway. This may ...
- Antibiotic resistance is a severe health threat. But there’s a glimmer of hope.on November 27, 2019 at 2:12 pm
Antibiotic resistance is the tendency of pathogens — bacteria and fungi — to fight back against antibiotic drugs, making some infections harder to treat, or untreatable altogether, one of the most ...
- Microbiologist laments misuse of antibiotic drugson November 27, 2019 at 1:05 am
“An antibiotic policy will improve patient care by promoting the best practices in antibiotics prophylaxis and therapy. It will ensure better use of resources by using cheaper drugs where possible and ...
- Early exposure to antibiotic drugs and risk for psychiatric disorders: a population-based studyon November 26, 2019 at 6:39 am
However, the risk from exposure in fetal life has been proposed to be confounded by familial factors. The hypothesis of this study is that antibiotic drug exposure during the fetal period and the ...
- Research yields potent antimicrobial that works against staph infectionon November 25, 2019 at 10:39 am
Research led by scientists from McMaster University has yielded a potent antimicrobial that works against the toughest infectious disease strains. The find could be the beginning of developing new ...
- Antibiotic-resistant bacteria are killing us. Here's how we can defeat these 'superbugs.'on November 25, 2019 at 3:04 am
Yet solutions — simple in principle — are possible. And they don’t require spending exorbitant amounts of money on new drugs that will fail in the manner of their predecessors. Instead, we can apply ...
via Bing News